ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.
 PMID: 26045705       2015       Hepatitis monthly
Result: Moreover, a comparison between baseline and post-baseline samples from these patients showed that the presence of rtL91I, rtN238H/T/S, rtC256G, rtN53S/T and rtY54N mutations reduced significantly after the initiation of TDF treatment (P < 0.05) (Table 4).
Table: L91I
Discussion: In addition, two mutations of rtL91I and rtN238H/T/S presented in 10% of baseline sequences from patients, were not detected in these patients after


  Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine.
 PMID: 25503289       2014       PloS one
Table: L91I


  Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.
 PMID: 24630522       2014       Diagnostic microbiology and infectious disease
Abstract: However, NAr mutations found in 6 isolates (37.5%) involved 7 positions including rtL91I, rtT128I, rtQ215P, rtF221Y, rtN238D, rtC256S, and rtI266G.


  Hepatitis B virus reverse transcriptase mutations in treatment Naive chronic hepatitis B patients.
 PMID: 23918533       2013       Journal of medical virology
Abstract: Other common mutations included rtD263E/S, rtM129L, rtF122L/V/I, rtS135Y/H, rtQ149K, rtL91I, rtH126R, rtC256S/G, rtY257W, rtS259T and rtE271D, which were present in 26.5% (9/34), 29.4% (10


  Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.
 PMID: 23596461       2013       Hepatitis monthly
Result: Common and frequent lamivudine-related amino acid substitutions were found in this study including N53K 3.68% (12/325), L80V/I 3.07% (each 5/325), L82M1.22% (4/325) L91I 7.06% (23/325), T128I 1,53% (5/325), L180M3.37% (11/325), and M204I2.76%(9/325) M204V 1.23% (4/325) see Figure 1.
Discussion: The results showed that viral mutations related to lamivudine, adefovir ,telbivudine, and entecavir resistance were discovered in patients who had never been treated with these drugs, with various mutation frequencies ranging between 1.23% (for M204V) and 7.06% (for L91I).


  Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
 PMID: 22078148       2012       Journal of clinical virology
Abstract: RESULTS: Dominance of a clone carrying L80LV, L91I, M204I, S219A, N238D, Y245H changes was detected in the last serum sample of the patient just before his death.


  Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
 PMID: 23026293       2012       Antiviral research
Abstract: Comparison with sequencing data of patients failing LMV or LAM+ADV therapy revealed an higher frequency of novel genotype-specific mutations if compared with naive patients: 3 mutations under LAM monotherapy in HBV-D (rtS85F; rtL91I; rtC256G) and 3 mutations under ADV therapy in HBV-A (rtI53V; rtW153R; rtF221Y).


  Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient.
 PMID: 22312387       2010       Hepatitis monthly
Table: L91I



Browser Board

 Co-occurred Entities




   Filtrator